Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) — Cash Flow Quality Index
Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has a Cash Flow Quality Index of 2.27x as of September 2025. Operating cash flow of CN¥76.07 Million exceeds net income of CN¥33.45 Million, indicating high earnings quality where cash backs reported profits. Explore Beijing Sun Novo Pharmaceutical Research cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Beijing Sun Novo Pharmaceutical Research Co Ltd Cash Flow Quality Index (2017–2025)
Historical Cash Flow Quality Index for Beijing Sun Novo Pharmaceutical Research Co Ltd across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 688621 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2025)
Year-by-year earnings quality comparison for Beijing Sun Novo Pharmaceutical Research Co Ltd. For live market cap and the full company financial profile, see how much is Beijing Sun Novo Pharmaceutical Research worth.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.46x | CN¥93.21 Million | CN¥203.87 Million | ▲ +141.3% |
| 2024 | 0.19x | CN¥32.02 Million | CN¥169.01 Million | ▼ -62.7% |
| 2023 | 0.51x | CN¥92.86 Million | CN¥182.90 Million | ▼ -22.8% |
| 2022 | 0.66x | CN¥103.96 Million | CN¥158.04 Million | ▼ -18.9% |
| 2021 | 0.81x | CN¥88.25 Million | CN¥108.79 Million | ▼ -4.5% |
| 2020 | 0.85x | CN¥62.99 Million | CN¥74.16 Million | ▼ -28.5% |
| 2019 | 1.19x | CN¥56.97 Million | CN¥47.93 Million | ▼ -45.7% |
| 2018 | 2.19x | CN¥44.11 Million | CN¥20.16 Million | ▼ -69.4% |
| 2017 | 7.14x | CN¥8.01 Million | CN¥1.12 Million | — |